COLD AND CO at the TIPS 2023

Since November 9, several laboratories have announced the development of a vaccine that is more than 90% effective. Pfizer-BioNtech laboratories present their first results obtained on a messenger RNA (mRNA) vaccine. What is the principle of this vaccine? What impact on its cold chain ? Historical vaccines with infectious agents Historically, the first vaccines were

Exposure of Cominarty and Moderna vaccines to room temperature for more than 3 minutes is irreversible as the vaccine is considered thawed. It can’t be re-frozen. In January 2021, the Cold Health Commission “Covid-19” of the « Association Française du Froid » (AFF) published several understanding notes, information and good practices of the cold chain around COVID-19 vaccines. 1.

While the French government has launched a general vaccination campaign (supported by the Institut National du Cancer) against HPV in French secondary schools, aimed at 5th graders, it is still estimated that almost 8 out of 10 people are exposed to Human Papilloma Virus (HPV) in the course of their lives. This high figure may

Cold-chain solutions company COLD & CO has teamed up with Blulog to provide a system for tracking temperatures in thermal, lightweight containers during the last mile of food delivery to customers.   RFID Journal, Jul 03, 2019   Several European delivery companies are striving to make the last mile of food delivery fast and ecological.

COLD & CO presents its logistical innovations for the transport of heat-sensitive products in the October 2019 issue of Informations Entreprise.   The cold chain represents about 15% of transport flows. Whether pharmaceutical or food products are transported internationally, regionally or locally, temperature-sensitive goods flows require a guarantee that temperatures are respected from the first to the

A topical challenge with the upcoming distribution of the COVID-19 vaccine The development and distribution of a COVID-19 vaccine raises several questions about the logistics of distributing health products. The challenge concerns both the number of doses to be dispensed, the countries and manufacturing sites, but also the temperature range to which the product will be